Skip to main content
. 2020 Mar 23;20:90. doi: 10.1186/s12935-020-1164-8

Table 2.

Resistance to cisplatin in each group and in two breast cell lines

Groups MCF-7 MDA-MB-231
IC50 (μmol/L) IC50 (μmol/L)
Control 12.52 ± 1.17 14.63 ± 1.27
NC 13.12 ± 1.34 15.24 ± 1.31
si-ZEB1-AS1 7.89 ± 0.87* 6.57 ± 0.83*
miR-129-5p mimic 8.64 ± 0.94* 5.38 ± 0.75*
miR-129-5p inhibitor 19.65 ± 1.65* 22.84 ± 1.49*
si-ZEB1-AS1 + miR-129-5p mimic 4.06 ± 0.42* 2.26 ± 0.41*

NC negative control, miR-129-5p microRNA-129-5p, ZEB1-AS1 zinc finger E-box binding homeobox 1 antisense 1

*p < 0.05 vs. the control group